2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2767

Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Evaluation of Modified Minimal Disease Activity upon Elimination of Each Component

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2758

Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Which Unmet Criteria Are More Prevalent Among Responders?

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2492

Mode of Administration in Rheumatoid Arthritis Treatments: An Exploration of Patient Preference for an ‘Ideal Treatment’

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2230

Models Using Claims-Based Administrative Data Are Poor Predictors of Rheumatoid Arthritis Disease Activity in VA Rheumatoid Arthritis (VARA) Patients

Health Services Research - Poster III

9:00AM-11:00AM: Abstract Number: 2697

Modulator Role of Inducible Costimulator (ICOS) in Spondyloarthritis Animal Model

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster II

9:00AM-11:00AM: Abstract Number: 2280

Monosodium Urate Crystal-Induced Inflammation Promotes Osteocyte Expression of Pro-Resorptive and Inflammatory Mediators: Implications for Erosive Gout

Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease

9:00AM-11:00AM: Abstract Number: 2281

Monosodium Urate Monohydrate (MSU) Crystals Induces Cartilage Degeneration By Accelerating Hypertrophy and Mineralization.

Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease

9:00AM-11:00AM: Abstract Number: 2401

Mucocutaneous Lesions and Recurrent Fevers in Patients with Trisomy 8 Mosaicism and Chromosome 8 Duplication

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous

9:00AM-11:00AM: Abstract Number: 2520

Multi-Biomarker Disease Activity (MBDA) Score and Prediction of Radiographic Progression in a Randomized Study of Patients with Early RA Treated with Methotrexate Alone or with Adalimumab

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2798

Multi-Center Validation of Platelet Bound C4d, a Biomarker for Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2411

Multiple Genetic Susceptibility Loci in Juvenile Idiopathic Arthritis Are Bound By a Set of Transcription Factors

Pediatric Rheumatology – Pathogenesis and Genetics - Poster

9:00AM-11:00AM: Abstract Number: 2405

Musculoskeletal Manifestations As Presenting Symptoms of Inflammatory Bowel Disease in Children and Adolescents

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous

9:00AM-11:00AM: Abstract Number: 2271

Mutation in Osteoprotegerin Gene: Early-Onset Osteoarthritis and Chondrocalcinosis in a US Family of Italian/German Ancestry

Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease

9:00AM-11:00AM: Abstract Number: 2430

Mutations in the Tyrosine-Protein Kinase Lyn Cause an Early-Onset Neutrophilic Vasculitis Syndrome

Pediatric Rheumatology – Pathogenesis and Genetics - Poster

9:00AM-11:00AM: Abstract Number: 2582

N-Acetylcysteine Regulates Osteoclastogenesis and Th17 Cell Differentiation in Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].